Research
Hormonal
Ethnicity influences beta-cell functional capacity, with Asians having lower beta-cell regenerative capacity and insulin secretion compared to Caucasians, leading to T2DM at lower BMI levels.
If you are of Asian descent, be aware that you may develop Type 2 Diabetes at a lower body weight than Caucasians. This is due to biological differences in beta-cell capacity. Prioritize weight management and lifestyle changes even if your BMI is in the 'normal' range.
GoodQualifiesMEDIUM confidence
Asians have less insulin secretion with higher insulin sensitivity compared with Caucasians... Asians have less beta-cell regenerative capacity compared with Caucasians... the lower beta-cell functional capacity in this population may contribute the different phenotype of T2DM between the two ethnicities.
Why this rating
Based on comparative studies between Japanese and Caucasian populations.
Source
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Yoshifumi Saisho · World Journal of Diabetes · 2015
DOI 10.4239/wjd.v6.i1.109
narrative_reviewCited 253×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Beta-cell dysfunction and loss of functional mass are present at the time of Type 2 Diabetes diagnosis and progressively decline by approximately 5% annually, independent of disease duration.Strong
- Preserving or recovering beta-cell functional mass is the critical therapeutic strategy for preventing and managing type 2 diabetes, primarily achieved by reducing beta-cell workload through lifestyle modification and weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →